Proteomics of Brain Trauma-associated Elevated Intracranial Pressure (ICP)

Sponsor
The University of Texas Health Science Center, Houston (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT00178659
Collaborator
TIRR/Mission Connect (Other), The Center for Clinical and Translational Sciences (CCTS) Clinical Research Unit at The University of Texas Health Science Center at Houston (Other)
260
1
245
1.1

Study Details

Study Description

Brief Summary

The specific aim of this research is to determine if the blood from brain-injured patients contains reproducible protein markers that appear prior to elevations in intracranial pressure (ICP).

Condition or Disease Intervention/Treatment Phase
  • Other: Blood/saliva samples for protein/molecular analysis

Detailed Description

One of the major causes of death following brain trauma is increased intracranial pressure (ICP). Currently, there are no effective ways to predict if the ICP of a patient will reach uncontrollable levels. Various cytokines (balance between pro-and anti-inflammatory) and other factors are thought to underlie increases in ICP. The specific aim of this research is to determine if the blood from brain-injured patients contains reproducible protein markers that appear prior to elevations in ICP. We propose to employ mass spectrometry, antibody array and ELISA to profile proteins in the serum of patients suffering from traumatic brain injury. These protein profiles will be compiled by a pattern recognition program that has the capacity to learn and make predictions based on the spectra and associated patient information. Each time a sample is analyzed, it is added to the database allowing the program to make increasingly accurate predictions. Protein profiles of patients with known ICP values will be analyzed. Our hypothesis is that alterations in serum protein composition will precede changes in intracranial pressure giving rise to predictable patterns that can be detected using large-scale proteomic analysis. After approximately 90 non-brain trauma and 90 brain-trauma patients are analyzed, if markers are found, the predictability of elevated ICP will be tested. If successful, this may aid the neurosurgeon in determining future courses of treatment.

Study Design

Study Type:
Observational
Anticipated Enrollment :
260 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Proteomics of Brain Trauma-associated Elevated Intracranial Pressure (ICP)
Study Start Date :
Jul 1, 2004
Anticipated Primary Completion Date :
Dec 1, 2024
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
1 healthy volunteers

Healthy volunteers to act as controls - Recruitment is complete for this cohort

Other: Blood/saliva samples for protein/molecular analysis
Bloods samples - healthy volunteers(1 time) head injury subjects (5 times). Blood and/or saliva samples mild TBI patients (2 times) and healthy volunteers (2 times)
Other Names:
  • blood samples
  • saliva samples
  • 2 head trauma

    Head trauma patients meeting enrollment criteria - Recruitment is complete for this cohort

    Other: Blood/saliva samples for protein/molecular analysis
    Bloods samples - healthy volunteers(1 time) head injury subjects (5 times). Blood and/or saliva samples mild TBI patients (2 times) and healthy volunteers (2 times)
    Other Names:
  • blood samples
  • saliva samples
  • 3 orthopedic injury

    The orthopedic injury cohort will include patients admitted to the ED able to provide informed consent with the following: Fracture confirmed radiographically No head trauma No other known inflammatory process or infection No history of neurological or psychiatric disorders or alcohol or drug dependency

    Other: Blood/saliva samples for protein/molecular analysis
    Bloods samples - healthy volunteers(1 time) head injury subjects (5 times). Blood and/or saliva samples mild TBI patients (2 times) and healthy volunteers (2 times)
    Other Names:
  • blood samples
  • saliva samples
  • 4 Mild TBI

    The mild TBI patients will be defined as those admitted to the ED experiencing, - Recruitment is complete for this cohort Non-penetrating head trauma manifesting one or more of the following: Loss of consciousness Post-traumatic amnesia Altered mental status Focal neurologic deficits, seizure GCS> 12 No abnormalities on CT other than contusion No operative Lesions Length of hospital stay < 48 hrs No other known inflammatory process or infection No history of neurological or psychiatric disorders or alcohol or drug dependency

    Other: Blood/saliva samples for protein/molecular analysis
    Bloods samples - healthy volunteers(1 time) head injury subjects (5 times). Blood and/or saliva samples mild TBI patients (2 times) and healthy volunteers (2 times)
    Other Names:
  • blood samples
  • saliva samples
  • Outcome Measures

    Primary Outcome Measures

    1. Elevated intracranial pressure [within the first 10 days post injury]

      Intracranial pressure >20mmHg

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    14 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • 14-65 years old

    • Non-penetrating brain injury

    • ICP monitor or

    • Healthy volunteer or

    The orthopedic injury cohort will include patients admitted to the ED able to provide informed consent with the following:

    1. Fracture confirmed radiographically

    2. No head trauma

    3. No other known inflammatory process or infection

    4. No history of neurological or psychiatric disorders or alcohol or drug dependency.

    or The mild TBI patients will be defined as those experiencing,

    1. Non-penetrating head trauma manifesting one or more of the following:
    • Loss of consciousness

    • Post-traumatic amnesia

    • Altered mental status

    • Focal neurologic deficits, seizure

    1. GCS> 12

    2. No abnormalities on CT other than contusion

    3. No operative Lesions

    4. Length of hospital stay < 48 hrs

    5. No other known inflammatory process or infection

    6. No history of neurological or psychiatric disorders or alcohol or drug dependency

    Exclusion Criteria:
    • Inability to obtain informed consent

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 The University of Texas, Houston Houston Texas United States 77030

    Sponsors and Collaborators

    • The University of Texas Health Science Center, Houston
    • TIRR/Mission Connect
    • The Center for Clinical and Translational Sciences (CCTS) Clinical Research Unit at The University of Texas Health Science Center at Houston

    Investigators

    • Principal Investigator: Pramod Dash, PhD, The University of Texas, Houston

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Georgene Hergenroeder, Associate Professor, Neurosurgery, The University of Texas Health Science Center, Houston
    ClinicalTrials.gov Identifier:
    NCT00178659
    Other Study ID Numbers:
    • HSC-MS-04-040
    • N-13-04-040
    First Posted:
    Sep 15, 2005
    Last Update Posted:
    Sep 13, 2021
    Last Verified:
    Sep 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Keywords provided by Georgene Hergenroeder, Associate Professor, Neurosurgery, The University of Texas Health Science Center, Houston
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 13, 2021